Glenmark Pharmaceuticals announced the launch of Nebzmart GFB Smartules and Glenmark Airz FB Smartules, the world's first nebulized, fixed-dose triple therapy for the treatment of Chronic Obstructive Pulmonary Disease (COPD).
Both products combine three proven medicines - Glycopyrronium, Formoterol, and Budesonide - to reduce airway obstruction, inflammation, and improve lung function and symptom control. As a single, easy-to-use nebulized therapy, it minimizes the burden of multiple medications. This marks a breakthrough as a new standard of care for COPD patients, especially those who struggle with using Metered Dose Inhalers (MDI) or Dry Powder Inhalers (DPI).
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
